CD4⁺⁺ CD28⁺⁺ lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft

By Schmidmaier Ralf   Then Cornelia   Schnabel Brigitte   Oduncu Fuat   Baumann Philipp   Straka Christian  

Cytotherapy, Vol. 13, Iss. 8, 2011-09 ,pp. : 987-992

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Predictors of high yield and purify of CD34⁺ cell-selected PBPC, collected from patients with multipe myeloma

By Webb I J   Scholssman R L   Jiroutek M   Doss D   Cohen C A   Freeman A   Schott D M   Anderson K C  

Cytotherapy, Vol. 1, Iss. 3, 1999-01 ,pp. : 175-182

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Impaired circulating myeloid DCs from myeloma patients

By Johnsen He   Kjærsgaard E   Taaning E   Svane Im   Do Th  

Cytotherapy, Vol. 6, Iss. 3, 2004-06 ,pp. : 196-203

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Analysis of factors affecting PBPC collection in low-weight children with malignant disorders

By Delgado J   Fernandez-jimenez Mc   Martinez A   Sastre A   Garcia-miguel P   Hernandez-navarro F   Arrieta R  

Cytotherapy, Vol. 6, Iss. 1, 2004-01 ,pp. : 43-49

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Cryopreserved mobilized autologous blood progenitors stored for more than 2 years successfully support blood count recovery after high-dose chemotherapy

By Cameron Giovanna   Tantiworawit Adisak   Halpenny Mike   Letcher Brenda   Berrigan Sue   Hindmarsh Karen   Giftakis Angeline   Fortier Johanne   O'Hoski Pamela   Hogge Donna  

Cytotherapy, Vol. 13, Iss. 7, 2011-08 ,pp. : 856-863

Ashgate Publishing Ltd

Access to resources Recommend Favorite